Prescribing information (external link)
LEQVIO® (inclisiran) is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:1
in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
The effect of LEQVIO® on cardiovascular morbidity and mortality has not yet been determined.1
For full safety information, please refer to the LEQVIO® Summary of Product Characteristics.
LEQVIO® resources
Explore our growing repository of resources designed to provide useful information on LEQVIO® and other relevant topics for healthcare professionals (HCPs) treating eligible patients with atherosclerotic cardiovascular disease.
Please note that this material should only be shared with patients for whom the decision to prescribe LEQVIO® has already been made.
This downloadable PDF can be shared with your LEQVIO® patients to provide them with further information on their condition and useful information regarding taking LEQVIO®.
Please do not share this web page directly with patients; instead, please direct them to the patient portal.
Please get in touch with us to speak to one of our Novartis representative
HCP, healthcare professional; LDL-C, low-density lipoprotein cholesterol.
References
LEQVIO® Summary of Product Characteristics.
UK | January 2026 | FA-11570143
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
